COTA’s Miruna Sasu: I left pharma to “turn the spigot on” in the real-world data industry

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Miruna Sasu spent more than 20 years as a digital health and innovation expert at life sciences companies—then came a realization:

“You can do all kinds of really cool technology things, but if you don’t have data, you can’t apply the technology; right?” Sasu said to The Cancer Letter. “Now that pharma companies can receive it and put it to good use, we want to turn the spigot on.”

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Matthew Bin Han Ong
Matthew Bin Han Ong
Table of Contents

YOU MAY BE INTERESTED IN

The Menarini Group and Stemline Therapeutics will present new and expanded data on Orserdu at the upcoming 2024 San Antonio Breast Cancer Symposium, held from Dec. 10-13. The company will bring real-world progression-free survival results of Orserdu in adult patients with ER+/HER2-, advanced or metastatic breast cancer. Additionally, the company will present updated efficacy results of elacestrant plus abemaciclib, along with a pooled safety analysis from phase Ib/2 of both the ELECTRA and ELEVATE trials.
Matthew Bin Han Ong
Matthew Bin Han Ong

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login